OBJECTIVES: To date, there are no robust head-to-head comparisons of tyrosine kinase inhibitors (TKIs) regarding treatment flow in chronic myeloid leukaemia (CML). The available evidence is limited to observational studies of small size. This study aims to understand treatment patterns of TKIs and relevant side effects in CML.

METHODS: Data from a large sample of 5,610 CML patients collected through a cross sectional survey from October 2016 to March 2018 across Spain, Italy, Germany, France and UK were analysed. Historic TKI-treatment records of patients receiving TKIs (treatment duration, reasons for discontinuation and side effects) were evaluated (n=894).

RESULTS: Most CML cases reported were receiving a 1st line treatment (84%; n=4,682) with 1^st generation TKIs being the most used (62%) vs